SCHEMBL24371423

SCHEMBL24371423

COC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C(N)C1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 5/20 0.76
POLB P06746 1/20 0.76
P2RX1 P51575 2/20 0.68
P2RX3 P56373 2/20 0.68
P2RX2 Q9UBL9 2/20 0.68
ADORA1 P30542 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
ADORA2A P29274 2/20 0.61
ADORA2B P29275 2/20 0.61
DPP4 P27487 1/20 0.61
MEN1 O00255 1/20 0.61
SLC28A1 O00337 1/20 0.61
MAP3K7 O43318 1/20 0.61
SLC28A2 O43868 1/20 0.61
GAPDH P04406 1/20 0.61
MAPK1 P28482 1/20 0.61
STAT6 P42226 1/20 0.61
PI4KA P42356 1/20 0.61
KMT2A Q03164 1/20 0.61
PI4K2B Q8TCG2 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41361 0.91 ADORA1 (0.74) ADORA3P2RX1P2RX3P2RX2ADORA1
SCHEMBL15338502 0.91 ADORA1 (0.74) ADORA3P2RX1P2RX3P2RX2ADORA1
SCHEMBL384075 0.91 ADORA1 (0.74) ADORA3P2RX1P2RX3P2RX2ADORA1
SCHEMBL15788449 0.91 ADORA1 (0.74) ADORA3P2RX1P2RX3P2RX2ADORA1
SCHEMBL15926827 0.91 ADORA1 (0.74) ADORA3P2RX1P2RX3P2RX2ADORA1
SCHEMBL29936504 0.91 ADORA1 (0.74) ADORA3P2RX1P2RX3P2RX2ADORA1
SCHEMBL15338536 0.91 ADORA1 (0.74) ADORA3P2RX1P2RX3P2RX2ADORA1
SCHEMBL21999233 0.88 ADORA3 (0.64) ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B
SCHEMBL21999782 0.88 NT5E (0.69) ADORA3POLBP2RX1P2RX3P2RX2
SCHEMBL381959 0.88 NT5E (0.69) ADORA3POLBP2RX1P2RX3P2RX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220125825-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS ALIGOS THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220125825-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS RNGTT, PHAX, HAVCR2 ADORA3 1372/4885POLB 56/4885P2RX1 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.